Dilated Cardiomyopathy (DCM)
Cardiovascular
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Gene Therapy
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Capricor TherapeuticsSAN DIEGO, CA
1 program1
Allogeneic Cardiosphere-Derived CellsPhase 11 trial
Active Trials
Rocket PharmaceuticalsNEW YORK, NY
1 program1
RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74Phase 1Gene Therapy1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Affinia TherapeuticsAFTX-201
Rocket PharmaceuticalsRP-A701 is a recombinant viral vector composed of an AAV serotype rh.74
Capricor TherapeuticsAllogeneic Cardiosphere-Derived Cells
Clinical Trials (3)
Total enrollment: 50 patients across 3 trials
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
Start: Mar 2026Est. completion: Dec 2032
Phase 1/2Not Yet Recruiting
NCT07137338Rocket PharmaceuticalsRP-A701 is a recombinant viral vector composed of an AAV serotype rh.74
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
Start: Jun 2026Est. completion: Jun 20298 patients
Phase 1Not Yet Recruiting
Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)
Start: Nov 2014Est. completion: Apr 202042 patients
Phase 1Unknown
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr
Associate Regulatory Affairs Specialist
Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr
Business Development Manager, Post Transplant, Cardio Thoracic
Thermo Fisher Scientific
Remote
Yesterday
Director, Medical Affairs
Abbott
Germany - Hesse - Eschborn
Yesterday
Therapy Development Manager
Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space